Shelf life (days): 730.0
Formulation: A solution in acetonitrile
Formal Name: N-[3-((dimethyl-d3)amino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-ergoline-8ß-carboxamide
Purity: ≥99% deuterated forms (d1-d6)
Formula Markup: C26H31D6N5O2
Formula Weight: 457.64084
CAS Number: 2738376-76-4
Notes: Cabergoline-d6 is intended for use as an internal standard for the quantification of cabergoline (Item No. 23934) by GC- or LC-MS. Cabergoline is a dopamine D2 receptor agonist (Ki = 0.912 nM in rat striatal homogenates).{41336} It is selective for dopamine D2 over D1 receptors (Ki = 6,935 nM). Cabergoline inhibits prolactin secretion in, and growth of, isolated rat pituitary tumor cells in a concentration-dependent manner, an effect that can be blocked by the dopamine D2 receptor antagonist haloperidol (Item No. 12014).{41337} Cabergoline reduces phosphorylation of mammalian target of rapamycin (mTOR) and induces the formation of LC3 puncta, a marker of autophagy, and apoptosis in MMQ rat pituitary cells.{41338} In vivo, cabergoline (0.25 mg/kg) stimulates motor activity and decreases dyskinesias in a cynomolgus monkey model of Parkinson's disease induced by MPTP.{41339} Formulations containing cabergoline have been used in the treatment of prolactinomas.